Volume 72, Issue 7, Pages (October 2007)

Slides:

Advertisements

Similar presentations

Home care assistance and the utilization of peritoneal dialysis

Advertisements

Volume 69, Issue 7, Pages (April 2006)

Beta blockers in the management of chronic kidney disease

Plasma sodium and hypertension

Microalbuminuria, peripheral artery disease, and cognitive function

Confounding: What it is and how to deal with it

John P. Middleton, Patrick H. Pun Kidney International

Volume 65, Issue 6, Pages (June 2004)

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Volume 71, Issue 8, Pages (April 2007)

Volume 70, Pages S21-S25 (December 2006)

Volume 69, Issue 2, Pages (January 2006)

Volume 72, Issue 9, Pages (November 2007)

A new era in phosphate binder therapy: What are the options?

Volume 70, Issue 11, Pages (December 2006)

Volume 70, Issue 7, Pages (October 2006)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The epidemiology of chronic kidney disease

G. Tripepi, K.J. Jager, F.W. Dekker, C. Wanner, C. Zoccali

Volume 71, Issue 11, Pages (June 2007)

U-shaped effect of eGFR and mortality

Volume 73, Pages S5-S17 (April 2008)

Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments R. Mishler, J.J. Sands, N.J. Ofsthun,

Volume 74, Issue 8, Pages (October 2008)

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Blood pressure targets in hemodialysis patients

Volume 61, Issue 4, Pages (April 2002)

Volume 69, Issue 10, Pages (May 2006)

Volume 70, Issue 7, Pages (October 2006)

Fructose intake as a risk factor for kidney stone disease

Volume 73, Issue 12, Pages (June 2008)

Volume 85, Issue 3, Pages (March 2014)

The third World Kidney Day: Looking back and thinking forward

Does reducing salt intake increase cardiovascular mortality?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Proteinuria and hypertensive nephrosclerosis in African Americans

Methods for guideline development

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 87, Issue 1, Pages (January 2015)

The kidney, a cardiovascular risk marker, and a new target for therapy

Volume 67, Pages S52-S54 (January 2005)

Volume 71, Issue 4, Pages (February 2007)

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

Circadian regulation of renal function

Prehypertension: is it relevant for nephrologists?

Volume 69, Issue 1, Pages (January 2006)

Volume 72, Issue 4, Pages (August 2007)

Volume 71, Issue 9, Pages (May 2007)

Carmine Zoccali, Francesca Mallamaci Kidney International

The course of the remnant kidney model in mice

Organ transplantation goes to the movies

Volume 72, Issue 2, Pages (July 2007)

Volume 70, Issue 7, Pages (October 2006)

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Is it the low-protein diet or simply the salt restriction?

Volume 75, Issue 1, Pages (January 2009)

Volume 70, Issue 3, Pages (August 2006)

Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate S. Aime, C. Canavese, P. Stratta Kidney International

Volume 70, Issue 5, Pages (September 2006)

H.J. Chin, H. Ro, H.J. Lee, K.Y. Na, D.-W. Chae Kidney International

Volume 75, Issue 7, Pages (April 2009)

Volume 68, Issue 3, Pages (September 2005)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Antioxidant therapy in hemodialysis patients: a systematic review

Tetany during bicarbonate loading test

Volume 73, Issue 11, Pages (June 2008)

Characteristics of sudden death in hemodialysis patients

Presentation transcript:

Volume 72, Issue 7, Pages 879-885 (October 2007) Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial G.L. Bakris, L. Ruilope, F. Locatelli, A. Ptaszynska, B. Pieske, J. de Champlain, M.A. Weber, I. Raz Kidney International Volume 72, Issue 7, Pages 879-885 (October 2007) DOI: 10.1038/sj.ki.5002455 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 CONSORT diagram for the IMPROVE study. Kidney International 2007 72, 879-885DOI: (10.1038/sj.ki.5002455) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 2 Adjusted geometric mean AER from baseline to week 20 (excluding patients with AER below 20 μg/min (randomized patients)).*Indicates adjusted geometric mean ratio (±s.e.). Treatment difference (ratio of adjusted geometric mean ratios)=0.922 (95% CI 0.711–1.195; P=0.54). Kidney International 2007 72, 879-885DOI: (10.1038/sj.ki.5002455) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 3 Percentage change in AER from baseline to end point (week 20) in the ramipril plus irbesartan and ramipril plus placebo groups by patient subgroup. Kidney International 2007 72, 879-885DOI: (10.1038/sj.ki.5002455) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 4 Mean change in blood pressure from baseline at 20 weeks. Adjusted mean change from baseline to week 20 in trough (a) SeDBP and (b) SeSBP. Mean baseline blood pressures measurements were 162.9/89.9 and 163.3/89.3 for the ramipril plus irbesartan and ramipril plus placebo groups, respectively. Kidney International 2007 72, 879-885DOI: (10.1038/sj.ki.5002455) Copyright © 2007 International Society of Nephrology Terms and Conditions